Artificial Intelligence in Health Care-Understanding Patient Information Needs and Designing Comprehensible Transparency: Qualitative Study.

Background: Artificial intelligence (AI) is as a branch of computer science that uses advanced computational methods such as machine learning (ML), to calculate and/or predict health outcomes and address patient and provider health needs. While these technologies show great promise for improving healthcare, especially in diabetes management, there are usability and safety concerns for both patients and providers about the use of AI/ML in healthcare management. Objectives: To support and ensure safe use of AI/ML technologies in healthcare, the team worked to better understand: 1) patient information and training needs, 2) the factors that influence patients' perceived value and trust in AI/ML healthcare applications; and 3) on how best to support safe and appropriate use of AI/ML enabled devices and applications among people living with diabetes. Methods: To understand general patient perspectives and information needs related to the use of AI/ML in healthcare, we conducted a series of focus groups (n=9) and interviews (n=3) with patients (n=40) and interviews with providers (n=6) in Alaska, Idaho, and Virginia. Grounded Theory guided data gathering, synthesis, and analysis. Thematic content and constant comparison analysis were used to identify relevant themes and sub-themes. Inductive approaches were used to link data to key concepts including preferred patient-provider-interactions, patient perceptions of trust, accuracy, value, assurances, and information transparency. Results: Key summary themes and recommendations focused on: 1) patient preferences for AI/ML enabled device and/or application information; 2) patient and provider AI/ML-related device and/or application training needs; 3) factors contributing to patient and provider trust in AI/ML enabled devices and/or application; and 4) AI/ML-related device and/or application functionality and safety considerations. A number of participant (patients and providers) recommendations to improve device functionality to guide information and labeling mandates (e.g., links to online video resources, and access to 24/7 live in-person or virtual emergency support). Other patient recommendations include: 1) access to practice devices; 2) connection to local supports and reputable community resources; 3) simplified display and alert limits. Conclusion: Recommendations from both patients and providers could be used by Federal Oversight Agencies to improve utilization of AI/ML monitoring of technology use in diabetes, improving device safety and efficacy.

Practice Transformation Driven through Academic Partnerships.

Evidence-based interventions have been shown to improve the quality of patient care, reduce costs, and improve overall health outcomes; however, adopting new published research and knowledge into practice has historically been slow, and requires an active, systematic approach to engage clinicians and healthcare administrators in the required change. Pharmacists have been identified as important agents of change and can enhance care delivery in primary care settings through evidence-based interventions. Utilizing the Consolidated Framework for Implementation Research (CFIR) we identify, assess, and share barriers and facilitators to program development, as well as growth and expansion efforts across five discrete, university-subsidized, embedded-pharmacy practices in primary care. We identified two overarching modifiable factors that influence current and future practice delivery and highlight the role of academia as an incubator for practice change and implementation: Data collection and information sharing. Conceptual frameworks such as CFIR help establish a common vernacular that can be used to facilitate systematic practice site implementation and dissemination of information required to support practice transformation.

The Effects of Carbohydrate-Restricted Dietary Patterns and Physical Activity on Body Weight and Glycemic Control.

PURPOSE OF REVIEW: Carbohydrate (CHO)-restricted dietary patterns (very-low-CHO < 25-50 g CHO/day; low CHO 50-130 g CHO/day) and physical activity are used for weight loss and type 2 diabetes (T2D) prevention and management. This review discusses evidence for effects of these lifestyle therapies on body weight and glycemic control. RECENT FINDINGS: Evidence supports the view that CHO-restricted interventions may be more effective than high-CHO, low-fat (HCLF) interventions in the short term for weight loss and glycemic control, but both produced similar levels of weight loss and glycemic control by 12 months. CHO-restricted dietary patterns resulted in a decreased use of diabetes medications. Benefits of CHO restriction were achieved at intakes that did not induce ketosis. Physical activity increases insulin sensitivity and reduces pancreatic beta-cell load, enhancing the effect of weight loss to delay or prevent T2D. A CHO-restricted dietary pattern may be a reasonable option for weight loss and T2D management for some individuals. Physical activity enhances weight management and cardiometabolic health.

Optimal Dietary Strategies for Prevention of Atherosclerotic Cardiovascular Disease in Diabetes: Evidence and Recommendations.

PURPOSE OF REVIEW: This review presents the current available evidence of the effects of several dietary patterns on atherosclerotic cardiovascular disease (ASCVD) risk in patients with type 2 diabetes (T2D). RECENT FINDINGS: Evidence demonstrates improvements in cardiovascular risk factors with some dietary patterns in the general population. However, evidence is limited for glycemic control and cardiovascular benefit in patients with T2D for Dietary Approaches to Stop Hypertension and plant-based dietary patterns. Evidence suggests that carbohydrate-restricted dietary patterns improve glycemic control and decrease the use of anti-hyperglycemic medications. The Mediterranean dietary pattern has the most evidence for glycemic control and decreased ASCVD risk in patients with T2D. There is no evidence on ASCVD outcomes in patients with T2D for any other dietary pattern. The Mediterranean dietary pattern has the most evidence for cardiovascular benefit in patients with T2D. Future research should examine the effect of dietary patterns on ASCVD outcomes.

Overview of the guidelines and evidence for the pharmacologic management of type 2 diabetes mellitus.

The number of novel treatment options for type 2 diabetes mellitus, including those with distinctive mechanisms of action, has risen sharply this decade, and health care providers must be aware of the drugs' safety and efficacy in order to provide patients with the best care possible. Guidelines for type 2 diabetes provide recommendations for initiating and continuing treatment that will enable patients to achieve glycemic control and maintain it over time. Several recently completed, large clinical trials have provided information pertaining to potential benefits and risks of achieving specific treatment goals, and medical professionals should consider applying the insights from these trials when optimizing care for their patients. The pharmacist plays an essential role in helping patients achieve and maintain tight glycemic control by assisting other health care providers in understanding and utilizing the guidelines as part of individualized treatment regimens.

The comparison of combination SSRI and PDE-5 inhibitor therapy to SSRI monotherapy in men with premature ejaculation.

OBJECTIVE: To evaluate whether combination therapy with a selective serotonin reuptake inhibitor (SSRI) and phosphodiesterase-5 (PDE-5) inhibitor is superior to SSRI monotherapy in the treatment of premature ejaculation. DATA SOURCES: A literature search of MEDLINE (January 1980-April 2011) and International Pharmaceutical Abstracts (January 1970-April 2011) was conducted using the search terms premature ejaculation, phosphodiesterase-5 inhibitor, and selective serotonin reuptake inhibitor. STUDY SELECTION AND DATA EXTRACTION: All English-language human studies assessing the use of a PDE-5 inhibitor and SSRI in the treatment of premature ejaculation were evaluated. Additional references were retrieved from reference citations. DATA SYNTHESIS: Premature ejaculation is a multi-component disorder with several treatment options. Studies have demonstrated that both SSRIs and PDE-5 inhibitors used as monotherapy can delay time to ejaculation. Four clinical trials have been conducted to compare the efficacy of SSRI monotherapy versus combination SSRI-PDE-5 inhibitor therapy for the treatment of premature ejaculation. All studies focused on the treatments' ability to delay time to ejaculation. A statistically significant delay in time to ejaculation was found in patients using both an SSRI and PDE-5 inhibitor when compared to those on an SSRI alone. Average time to ejaculation was increased by approximately 50-78 seconds in patients using combination therapy when compared to monotherapy. The data also show greater delay in ejaculation with combination therapy in patients previously using SSRI monotherapy but dissatisfied with its effects. Adverse drug reactions including headache and flushing were higher in the combination group. CONCLUSIONS: Although a modest delay in ejaculation is seen when using an SSRI and PDE-5 inhibitor together, the combination also comes with increased risks for adverse drug reactions and is more expensive. SSRI monotherapy should continue to be first-line treatment for premature ejaculation due to a better adverse drug reaction profile, lower cost, and high efficacy. Combination therapy may be prescribed for those who fail SSRI monotherapy or have concomitant erectile dysfunction.